Xu and colleagues demonstrated that EZH2 acts as a coactivator of androgen receptor-associated complexes to support castration-resistant prostate cancer (CRPC) growth, suggesting novel combination therapies for the treatment of metastatic, hormone-refractory prostate cancer [9]. The gene discussed is EZH2; the disease is Familial prostate cancer.